Other equities analysts have also issued reports about the stock. JPMorgan Chase & Co. raised shares of GRIFOLS S A/S from a neutral rating to an overweight rating and lifted their price target for the stock from $21.00 to $22.50 in a report on Thursday, June 27th. Zacks Investment Research lowered shares of GRIFOLS S A/S from a hold rating to a sell rating in a report on Tuesday, October 15th. Finally, ValuEngine raised shares of GRIFOLS S A/S from a sell rating to a hold rating in a report on Wednesday, October 2nd. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the stock. GRIFOLS S A/S presently has a consensus rating of Hold and an average price target of $20.75.
NASDAQ GRFS opened at $20.80 on Wednesday. The firm’s fifty day simple moving average is $20.46 and its two-hundred day simple moving average is $20.25. The company has a current ratio of 2.68, a quick ratio of 0.95 and a debt-to-equity ratio of 1.38. GRIFOLS S A/S has a 12-month low of $17.42 and a 12-month high of $23.03. The firm has a market capitalization of $14.22 billion, a P/E ratio of 17.78, a P/E/G ratio of 1.32 and a beta of 1.06.
GRIFOLS S A/S (NASDAQ:GRFS) last released its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.33. GRIFOLS S A/S had a net margin of 11.82% and a return on equity of 14.88%. The business had revenue of $1.42 billion for the quarter, compared to analyst estimates of $1.38 billion. As a group, sell-side analysts predict that GRIFOLS S A/S will post 1.23 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently made changes to their positions in GRFS. Thomas White International Ltd. purchased a new stake in shares of GRIFOLS S A/S during the second quarter valued at $84,000. Assetmark Inc. grew its holdings in shares of GRIFOLS S A/S by 453.8% during the second quarter. Assetmark Inc. now owns 6,363 shares of the biotechnology company’s stock valued at $134,000 after buying an additional 5,214 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its holdings in shares of GRIFOLS S A/S by 24.2% during the second quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 7,818 shares of the biotechnology company’s stock valued at $165,000 after buying an additional 1,522 shares during the last quarter. First Light Asset Management LLC purchased a new stake in shares of GRIFOLS S A/S during the second quarter valued at $215,000. Finally, Blackhawk Capital Partners LLC. purchased a new stake in shares of GRIFOLS S A/S during the second quarter valued at $254,000. 17.99% of the stock is currently owned by hedge funds and other institutional investors.
About GRIFOLS S A/S
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.
See Also: Market Timing
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.